Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK.
Br J Cancer. 2013 Mar 5;108(4):908-13. doi: 10.1038/bjc.2013.22. Epub 2013 Jan 31.
Several new assays have been developed for high-risk HPV testing of cervical samples; we compare six HPV tests in a screening population.
Residual material from liquid-based PreservCyt samples was assayed. Four tests (Hybrid Capture 2, Cobas, Abbott and Becton-Dickinson (BD)) measured HPV DNA while two used RNA (APTIMA and NorChip).
Positivity rates ranged from 13.4 to 16.3% for the DNA-based tests with a significantly lower positivity rate for the Abbott assay. The Gen-Probe APTIMA assay was positive in 10.3% of women, which was significantly lower than all the DNA tests; the NorChip PreTect HPV-Proofer test was much lower at 5.2%. 40 CIN2+ cases were identified, of which 19 were CIN3+. All CIN3+ cases were HPV positive by all tests except for one, which was negative by the Abbott assay and five which were negative by the NorChip test.
All HPV tests except NorChip showed high sensitivity for high-grade lesions positive by cytology, suggesting co-testing is unnecessary when using HPV tests. Positivity rates in cytology-negative specimens were similar for the DNA-based tests, but lower for the APTIMA test suggesting this maintains the high sensitivity of DNA tests, but with better specificity.
已经开发出几种用于宫颈样本高危 HPV 检测的新检测方法；我们在筛查人群中比较了六种 HPV 检测方法。
对液基 PreservCyt 样本的剩余材料进行了检测。四项检测（杂交捕获 2 型、Cobas、雅培和 BD）测量 HPV DNA，而两项检测使用 RNA（APTIMA 和 NorChip）。
DNA 检测的阳性率从 13.4%到 16.3%不等，雅培检测的阳性率明显较低。基因探针 APTIMA 检测在 10.3%的女性中呈阳性，明显低于所有 DNA 检测；NorChip PreTect HPV-Proofer 检测则低得多，为 5.2%。发现 40 例 CIN2+病例，其中 19 例为 CIN3+。除了一个病例，所有的 HPV 检测均为阳性，该病例被雅培检测法检测为阴性，还有五个病例被 NorChip 检测法检测为阴性，而所有的 CIN3+病例均被所有检测方法检测为阳性。
除了 NorChip 之外，所有 HPV 检测方法对于细胞学阳性的高级别病变都显示出很高的敏感性，这表明当使用 HPV 检测方法时，联合检测是不必要的。在细胞学阴性的标本中，DNA 检测的阳性率相似，但 APTIMA 检测的阳性率较低，这表明该方法保持了 DNA 检测的高敏感性，但具有更好的特异性。
